192 related articles for article (PubMed ID: 37729017)
21. Combined use of PI3K and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutations.
Jiang ZB; Huang J; Xie C; Li X; Liu L; He J; Pan H; Huang L; Fan XX; Yao XJ; Xie Y; Li N; Liu L; He JX; Leung EL
Oncol Rep; 2016 Jul; 36(1):365-75. PubMed ID: 27121230
[TBL] [Abstract][Full Text] [Related]
22. Caveolin-1 promotes the tumor suppressor properties of oncogene-induced cellular senescence.
Volonte D; Vyas AR; Chen C; Dacic S; Stabile LP; Kurland BF; Abberbock SR; Burns TF; Herman JG; Di YP; Galbiati F
J Biol Chem; 2018 Feb; 293(5):1794-1809. PubMed ID: 29247004
[TBL] [Abstract][Full Text] [Related]
23. Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC.
Liu W; Yin Y; Wang J; Shi B; Zhang L; Qian D; Li C; Zhang H; Wang S; Zhu J; Gao L; Zhang Q; Jia B; Hao L; Wang C; Zhang B
Oncotarget; 2017 Jan; 8(1):179-190. PubMed ID: 27329725
[TBL] [Abstract][Full Text] [Related]
24. Integrin-linked kinase (ILK) regulates KRAS, IPP complex and Ras suppressor-1 (RSU1) promoting lung adenocarcinoma progression and poor survival.
Nikou S; Arbi M; Dimitrakopoulos FD; Sirinian C; Chadla P; Pappa I; Ntaliarda G; Stathopoulos GT; Papadaki H; Zolota V; Lygerou Z; Kalofonos HP; Bravou V
J Mol Histol; 2020 Aug; 51(4):385-400. PubMed ID: 32592097
[TBL] [Abstract][Full Text] [Related]
25. Selective targeting of the oncogenic
Gao Q; Ouyang W; Kang B; Han X; Xiong Y; Ding R; Li Y; Wang F; Huang L; Chen L; Wang D; Dong X; Zhang Z; Li Y; Ze B; Hou Y; Yang H; Ma Y; Gu Y; Chao CC
Theranostics; 2020; 10(11):5137-5153. PubMed ID: 32308773
[No Abstract] [Full Text] [Related]
26. miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway.
Sun W; Ping W; Tian Y; Zou W; Liu J; Zu Y
Cell Physiol Biochem; 2018; 51(5):2160-2171. PubMed ID: 30522099
[TBL] [Abstract][Full Text] [Related]
27. The let-7a microRNA protects from growth of lung carcinoma by suppression of k-Ras and c-Myc in nude mice.
He XY; Chen JX; Zhang Z; Li CL; Peng QL; Peng HM
J Cancer Res Clin Oncol; 2010 Jul; 136(7):1023-8. PubMed ID: 20033209
[TBL] [Abstract][Full Text] [Related]
28. Cell-type specific tumorigenesis with Ras oncogenes in human lung epithelial cells.
Kumazaki M; Shimomura I; Kiyono T; Ochiya T; Yamamoto Y
Biochem Biophys Res Commun; 2020 Apr; 525(2):483-490. PubMed ID: 32111352
[TBL] [Abstract][Full Text] [Related]
29. Combination therapy with KRAS siRNA and EGFR inhibitor AZD8931 suppresses lung cancer cell growth in vitro.
Zarredar H; Pashapour S; Ansarin K; Khalili M; Baghban R; Farajnia S
J Cell Physiol; 2019 Feb; 234(2):1560-1566. PubMed ID: 30132854
[TBL] [Abstract][Full Text] [Related]
30. Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation.
Sheffels E; Sealover NE; Wang C; Kim DH; Vazirani IA; Lee E; M Terrell E; Morrison DK; Luo J; Kortum RL
Sci Signal; 2018 Sep; 11(546):. PubMed ID: 30181243
[TBL] [Abstract][Full Text] [Related]
31. Oncogenic KRAS promotes growth of lung cancer cells expressing SLC3A2-NRG1 fusion via ADAM17-mediated shedding of NRG1.
Shin DH; Kim SH; Choi M; Bae YK; Han C; Choi BK; Kim SS; Han JY
Oncogene; 2022 Jan; 41(2):280-292. PubMed ID: 34743207
[TBL] [Abstract][Full Text] [Related]
32. Salvianolic acid F suppresses KRAS-dependent lung cancer cell growth through the PI3K/AKT signaling pathway.
Hou X; Zhou C; Liang Z; Qiu H; Zhou Z; Zheng H; Li Z; Wang Y; Qi X; Lu L; Cao Y; Zheng J
Phytomedicine; 2023 Dec; 121():155093. PubMed ID: 37783131
[TBL] [Abstract][Full Text] [Related]
33. Foxm1 transcription factor is required for the initiation of lung tumorigenesis by oncogenic Kras(G12D.).
Wang IC; Ustiyan V; Zhang Y; Cai Y; Kalin TV; Kalinichenko VV
Oncogene; 2014 Nov; 33(46):5391-6. PubMed ID: 24213573
[TBL] [Abstract][Full Text] [Related]
34. Cisplatin and Pemetrexed Have Distinctive Growth-inhibitory Effects in Monotherapy and Combination Therapy on
Mohiuddin M; Kasahara K
Cancer Genomics Proteomics; 2021; 18(4):579-590. PubMed ID: 34183390
[TBL] [Abstract][Full Text] [Related]
35. MiR-181a-5p inhibits cell proliferation and migration by targeting Kras in non-small cell lung cancer A549 cells.
Ma Z; Qiu X; Wang D; Li Y; Zhang B; Yuan T; Wei J; Zhao B; Zhao X; Lou J; Jin Y; Jin Y
Acta Biochim Biophys Sin (Shanghai); 2015 Aug; 47(8):630-8. PubMed ID: 26124189
[TBL] [Abstract][Full Text] [Related]
36. Targeting KRAS Mutant Lung Cancer Cells with siRNA-Loaded Bovine Serum Albumin Nanoparticles.
Mehta A; Dalle Vedove E; Isert L; Merkel OM
Pharm Res; 2019 Jul; 36(9):133. PubMed ID: 31289919
[TBL] [Abstract][Full Text] [Related]
37. Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.
Sunaga N; Kaira K; Imai H; Shimizu K; Nakano T; Shames DS; Girard L; Soh J; Sato M; Iwasaki Y; Ishizuka T; Gazdar AF; Minna JD; Mori M
Oncogene; 2013 Aug; 32(34):4034-42. PubMed ID: 22964644
[TBL] [Abstract][Full Text] [Related]
38. Non-Redundant and Overlapping Oncogenic Readouts of Non-Canonical and Novel Colorectal Cancer KRAS and NRAS Mutants.
Alcantara KMM; Malapit JRP; Yu RTD; Garrido JAMG; Rigor JPT; Angeles AKJ; Cutiongco-de la Paz EM; Garcia RL
Cells; 2019 Dec; 8(12):. PubMed ID: 31816869
[TBL] [Abstract][Full Text] [Related]
39. Differential Effects of Variations at Codon 106 on Sprouty2 Functions in Lung Cancer-Derived Cells.
Kral R; Doriguzzi A; Mayer CE; Krenbek D; Setinek U; Sutterlüty-Fall H
J Cell Biochem; 2016 Aug; 117(8):1822-32. PubMed ID: 26727965
[TBL] [Abstract][Full Text] [Related]
40. Polyisoprenylated Cysteinyl Amide Inhibitors Deplete K-Ras and Induce Caspase-dependent Apoptosis in Lung Cancer Cells.
Nkembo AT; Amissah F; Ntantie E; Poku RA; Salako OO; Ikpatt OF; Lamango NS
Curr Cancer Drug Targets; 2019; 19(10):838-851. PubMed ID: 30914025
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]